



DTIM KWF

Dutch Tumor Immunology Meeting

Thursday June 15, 2023

09.30-09.55 **Registration & Coffee/Tea**

09.55-10.00 **Welcome**

Please Note; Selected abstract-presenters have exactly 15 minutes to present their data, including a few minutes discussion. Please make sure your presentation is on the computer before the session starts.

10.00-11.15 **Oral presentation Session 1**

Session chair: Tamara Verkerk

Vaccination against Secreted Frizzled-Related Protein 2 as anti-cancer therapy

Karlijn van Loon, PhD candidate, Amsterdamumc

The macrophage-T cell axis in the success and failure of immunotherapy

Marit van Elsas, PhD candidate, LUMC

Identification of hepatocyte-restricted antigens, epitopes, and T cell receptors to treat recurrent hepatocellular carcinoma after liver transplantation

Dian Kortleve, PhD candidate, Erasmusmc

Impact of tertiary lymphoid structures on the tumor-specific T cell landscape and response to PD-1 blockade

Nadine Slingerland, PhD candidate, NKI

Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells

Isabel Britsch, PhD candidate, UMCG

11.15-11.40 **Coffee/Tea Break**

11.40-12.40 **Oral presentation Session 2**

Session chair: Amy Kessler

Evaluation of Therapeutic and Immunological Action of CAIX-Targeted Lutetium-177 Radionuclide Therapy Combined with Immune Checkpoint Inhibition

Simone Kleinendorst, PhD candidate, Radboudumc

MHC-E, the ligand for checkpoint NKG2A, is also engaged by LILRB1 on myeloid cells

Jim Middelburg, PhD candidate, LUMC

Cis-targeting IL-2 to CD8 T cells induces distinct TCR-dependent and independent activation programs in human

Paulien Kaptein, PhD candidate, NKI

Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell derived-extracellular vesicles

Xiurong Ke, PhD candidate, UMCG

12.40-13.00

Dr. Delphi Coppens

Programmacoördinator cel- en gentherapie, KWF

“Current & Future research funding”

13.00-14.00

Lunch

14.00-15.15

Oral presentation Session 3

Session chair: Darshak Bhatt

ZFP36L2 regulates production of IFN γ in CD8+ T cells during prolonged T cell activation

Nordin Zandhuis, PhD candidate, Sanquin

Overcoming tumor-derived PGE2 suppression by targeting E-prostanoid receptor signalling in myeloid cells

Jorge Cuenca Escalona, PhD candidate, Radboudumc

Personalized identification of neoantigen-specific TCRs using synthetic TCR library screens

Ziva Moravec, PhD candidate, NKI

Neutralizing antibodies represent a barrier to tumor infection by oncolytic reovirus but permit effective reovirus and T-cell-based anticancer combination therapy

Christianne Groeneveldt, PhD candidate, LUMC

High plasma cell presence in oral cancers with high frequencies of tumor-infiltrating B cells identified by transcriptional and spatial profiling

Dennis Nijenhuis, PhD candidate, Amsterdamumc

15.15-15.30

Coffee/Tea Break

15.30-16.30

KWF workshop:

Science in Action: Creating Real-word Impact

Dr. Saharla Ahmed

senior business developer Oncode Valorization team:

“Valorization: Translating cancer research into clinical impact”

Dr. Laurel Schunselaar,

Academic pharma LUMC

“Academic pharma, to bridge the lab to life gap”

Laptop sessions:

Please note: Each laptop session consists of 3 rounds of 5 min laptop presentations followed by 3 minutes of discussion. Laptop presenters, please bring a fully charged laptop with your presentation to the session.

16:30-17:00 Laptop Session 1

Table 1: STAPLER: Efficient learning of TCR-peptide specificity prediction from full-length TCR-peptide data

Marius Messemaker, NKI

Table 2: Mutations in FLT3 and RUNX1 create HLA class I-restricted neoantigens on AML that can be targeted by immunotherapy

Nadine Struckman, LUMC

Table 3: Evaluating immunogenicity of oncolytic Semliki Forest virus in human cancer spheroids

Darshak Bhatt, UMCG

Table 4: A robust in vitro model to study M2-like human macrophage-mediated suppression of autologous CD8+ T cells

Rui Coelho, Erasmusmc

Table 5: Boosting Natural Killer cell immunity: improving a future without treatment for CML patients

Ayla Grotens, Radboudumc

Table 6: Development of a production process to generate CD8+ T cell-enriched tumor infiltrating lymphocyte (TIL) products for patients with solid cancers

Liselotte Tas, NKI

Table 7: Unraveling functional consequences of tumour-mediated galectin downregulation in dendritic cells

Andrea Rodgers Furones, Radboudumc

Table 8: Bifunctional antibodies: Tumor targeted blockade of innate immune checkpoints for the treatment of Neuroblastoma

Fabian Schuurmans, Radboudumc

Table 9: cGAS localization and activation: the key towards effective radiotherapy induced immune activation?

Vera Mekers, Radboudumc

Table 10: T cell infiltration in primary uveal melanoma correlates with genetic profile classification

Mark Sweep, Radboudumc

17:00-17:30 Laptop Session 2

Table 1: HLA peptidome analysis of synthetic long peptide-fed human dendritic cells for vaccine target selection

Amy Kessler, Erasmusmc

Table 2: Exploiting IL-2 co-engagement to enhance the efficacy of redirected CMV-specific T cells to eliminate carcinoma cells

Lisanne Koll, UMCG

Table 3: Engineered multi-functional immunoliposomes bridging T cells to melanoma

Ziyun Cheng, Erasmusmc

Table 4: Mutually exclusive contribution of BCR autonomous signaling and oncogenic driver mutations in DLBCL

Janneke Eken, LUMC

Table 5: Mapping Dendritic Cell Subsets in the Tumor Microenvironment by Multiplex Immunohistochemistry

Iris van der Hoorn, Radboudumc

Table 6: Expression of PD-1 on tumor-infiltrating T-lymphocytes as determinant of the head and neck cancer tumor immune microenvironment

Tara Muijlwijk, Amsterdamumc

Table 7: The anti-tumor response of NK cells is inhibited by elevated expression of neolactoseries glycosphingolipids on tumor cells

Anouk Pappot, Sanquin

Table 8: Upscaled manufacturing of an off-the-shelf stem cell-derived natural killer cell therapy for cancer

Laura Hooijmaijers, Radboudumc

Table 9: Combination of vaccination and CAR T cell therapy for solid tumor treatment

Gabriela Wachholz, Amsterdamumc

Table 10: Evolution of the lung adenocarcinoma tumour microenvironment

Xiaofei Yu, Amsterdamumc

17:30-18:00 Laptop Session 3

Table 1: Laminin $\alpha 4$:

Lauren Myburgh, Amsterdamumc

Table 2: Repurposing pre-existing anti-CMV immunity as novel treatment for CD19pos hematological malignancies

Anne van Wijngaarden, UMCG

Table 3: The risk of non-melanoma skin cancer in vitiligo patients: a review and meta-analysis on the association, and the potential mechanisms

Alex Rooker, Amsterdamumc

Table 4: CD38 targeting in Multiple Myeloma

Andrea Abel, Radboudumc

Table 5: In-depth characterization of adenosine pathway in hepatocellular carcinoma (HCC)
Patrick Boor, Erasmusmc

Table 6: Investigating the impact of DNA damage repair deficiency on tumor growth and anti-tumor immune responses in prostate cancer
Nina van Campen, Radboudumc

Table 7: A novel bispecific antibody for EpCAM-directed inhibition of the PD-L1 immune checkpoint on tumor-derived exosomes
Emily Ploeg, UMCG

Table 8: Characterization of tumor microenvironment remodeling following treatment, to rationalize therapeutic combinations for non-small cell lung cancer
Sofie Koomen, Amsterdamumc

Table 9: A mouse model for CD4 T cell dysfunctionality in cancer
Felicia Spitzer, LUMC

Tabel 10: T-cell and Humoral Responses to COVID-19 mRNA Vaccination in Patients with Hematologic Malignancies
Cilia R Pothast, LUMC

18.00-18.15 *Short biobreak*

18.15-19.15 **Keynote speaker 1**

Dr. Brad Nelson

Deeley Research Centre, BC Cancer, Victoria, BC, Canada

“B cells: the immune system's secret weapon against tumor heterogeneity?”

19.15-20.30 *Dinner*

20.30-21.30 **Keynote speaker 2**

Prof. Dr. Andy Sewell

Division of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, UK

“The secret of success: What do T-cells target during successful clearance of solid cancer”

21.30-00.00 **Networking party**



Friday June 16, 2023

9.00-10.30

Oral presentation Session 4

Session chair: Andrea Rodgers Furones

Melanoma survivors show unique kinetics of CD4 T cell subsets upon treatment with anti-PD1
H. Emrah Balcioglu, Erasmusmc

Microbiota-derived metabolites are crucial for immune checkpoint blockade response via the activation Vδ2+ unconventional T cells
Iris Mimpfen, PhD candidate, NKI

Tissue resident memory T cell development and exhaustion in pancreatic cancer
Hester Heimans, PhD candidate, LUMC

Improving stem cell-derived natural killer cell functionality against ovarian carcinoma with IL-15 transpresentation
Marcos Vidal Manrique, PhD candidate, Radboudumc

Perivascular containment of T cells in IDH-mutant astrocytoma associates with high abundance of gemistocytic tumor cells and reactive microglia
Levi van Hijfte, PhD candidate, Erasmusmc

Epigenetic Modulation of CD8+ T Cells for TCR-T cell therapy by targeting the histone methyltransferase DOT1L
Maxime Kempers, PhD candidate, NKI

10.30-11.00

Coffee/Tea Break

11.00-12.00

Keynote speaker 3

Prof. Dr. Sjoerd van der Burg

Medical Oncology, Onco Institute, Leiden University Medical Center, Leiden, the Netherlands

“The interaction between T cells and leukocytes governing failure and success in immunotherapy”

12.00-13.00

Oral presentation Session 5 (session chair: Elisabeth Huijbers)

Immunotherapy Targeting Mutant Nucleophosmin-1 On Acute Myeloid Leukemia
Georgia Koutsoumpli, LUMC

Classical conditioning to improve checkpoint inhibition efficacy in colon cancer
Chiara Jongerius, Amsterdamumc

An atlas and compass of immune-cancer-microbiome interactions conducive to prolonged survival in colon cancer patients
Jessica Roelands, LUMC

MCLA-145, an anti CD137×PD-L1 Bispecific antibody, induces T cell activation and proliferation in ex vivo models of hepatocellular carcinoma
Jyaysi Desai, Erasmusmc

13.00-13.05 **AIO Award Ceremony**

13.05-14.00 **Lunch**

Thanks to our sponsors for supporting this meeting:

